Biomab EGFR 50 mg Injection contains Nimotuzumab, a targeted monoclonal antibody used in the treatment of EGFR-positive cancers, including head and neck cancer, colorectal cancer, and nasopharyngeal carcinoma. It works by blocking the Epidermal Growth Factor Receptor (EGFR), preventing cancer cell growth and tumor progression.

This therapy is widely used in targeted oncology treatment to improve survival and disease control.

⚙️ How Nimotuzumab Works

Nimotuzumab binds to the EGFR receptor on cancer cells and:

• Blocks tumor growth signaling

• Inhibits cancer cell proliferation

• Enhances immune-mediated cancer cell destruction

• Slows tumor spread and progression

🩺 Uses of Biomab EGFR Injection

• Head and Neck Squamous Cell Carcinoma

• EGFR-positive Colorectal Cancer

• Nasopharyngeal Carcinoma

• Glioma (Brain Tumors)

• Other EGFR-expressing solid tumors

💡 Benefits of Biomab EGFR 50 mg Injection

• Targeted cancer therapy with fewer side effects

• Effective EGFR inhibition

• Helps control tumor growth and spread

• Improves treatment outcomes and survival

• Suitable for combination chemotherapy

📌 Dosage & Administration

• Given as an intravenous (IV) infusion

• Dosage based on cancer type and patient weight

• Administered under oncologist supervision

• Not for self-administration

⚠️ Possible Side Effects

• Fever and chills

• Rash or skin reactions

• Fatigue

• Headache

• Nausea

• Infusion-related reactions

Seek medical help if severe allergic reactions occur.

🚫 Precautions & Warnings

• Prescription-only oncology drug

• Monitor liver and immune function

• Avoid during pregnancy unless medically advised

• Use only in hospital or cancer centers

🏥 Storage Instructions

• Store at 2°C–8°C (Refrigerated)

• Do not freeze

• Protect from light

• Keep out of reach of children

📦 Packaging Details

• Strength: 50 mg

• Form: Injection

• Pack Size: Single-use vial

• Manufacturer: Biocon Ltd.